%0 Journal Article
%T Atrial Cardiomyopathy Predicts the Functional Outcome and Mortality in Stroke Patients.
%A Liu X
%A Wang Y
%A Ding L
%A Hu R
%A Zhang Y
%A Zhang W
%A Pei L
%A Cao Y
%A Fang H
%A Liu K
%A Sun S
%A Wu J
%A Buonanno FS
%A Ning M
%A Xu Y
%A Song B
%J J Atheroscler Thromb
%V 0
%N 0
%D 2024 Apr 19
%M 38644203
%F 4.394
%R 10.5551/jat.64756
%X <B>OBJECTIVE: </B>Atrial cardiomyopathy (ACM) is characterized by atrial dysfunction. This study aims to assess the prognostic significance of ACM in patients with noncardioembolic stroke (NCS).<BR><B>METHODS: </B>Patients with NCS within seven days of onset were prospectively enrolled between January 2019 and December 2020. ACM was defined as either an N-terminal pro-brain natriuretic peptide (NT-pro BNP) ＞250 pg/ml or a P-terminal force in precordial lead V1 (PTFV1) ≥ 5000µV·ms. A poor functional outcome was determined as a score of 3-6 on the modified Rankin Scale (mRS) within a 2-year follow-up period. Logistic regression and Cox regression analyses were employed to examine the relationship between ACM and the long-term prognosis of patients with NCS.<BR><B>RESULTS: </B>A total of 1,346 patients were enrolled, of whom 299 (22.2%) patients were diagnosed with ACM. A total of 207(15.4%) patients experienced a poor functional outcome, and 58 (4.3%) patients died. A multivariate logistic regression analysis indicated that ACM was significantly associated with a poor functional outcome in NCS patients [adjusted odds ratio (aOR): 2.01; 95% confidence interval (CI): 1.42-2.87; p＜0.001]. Additionally, a multivariate Cox regression analysis showed that an NT-pro BNP ＞250 pg/ml was significantly associated with an increased risk of all-cause mortality [adjusted hazard ratio (aHR), 2.51; 95% CI: 1.42-4.43; p=0.001].<BR><B>CONCLUSIONS: </B>ACM may serve as a novel predictor of a poor long-term functional outcome in patients with NCS. Elevated NT-pro BNP levels (＞250 pg/ml) were found to be associated with a higher risk of all-cause mortality. These findings warrant further validation in multicenter studies.